Pipeline

SCIENCE SOURCED WORLDWIDE

LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates

Global Clinical Trials Status

Cardiovascular

Phase 1

Phase 2

Phase 3/Pivotal

Mavacamten

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Non-obstructive Hypertrophic Cardiomyopathy (nHCM)

Precision Diastolic Disease (HFpEF)

Oncology

Phase 1

Phase 2

Phase 3/Pivotal

NBTXR3

Head and Neck Cancer

Solid tumor IO combinations

Infigratinib (BGJ398)

First-line Cholangiocarcinoma (1LCCA)

Second-line Cholangiocarcinoma (2LCCA)*

Gastric Cancer and Other FGFR-Driven Tumors

*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).

BBP-398

SHP2 Inhibitor for RTK Cancers

Ophthalmology

Phase 1

Phase 2

Phase 3/Pivotal

TP-03

Demodex blepharitis

Meibomian gland disease

Inflammatory Disease

Phase 1

Phase 2

Phase 3/Pivotal

Omilancor

Ulcerative Colitis

Crohn’s Disease

NX-13

Ulcerative Colitis

Crohn’s Disease

LYR-210

Chronic Rhinosinusitis (CRS)

Pipeline

Our current pipeline

SCIENCE SOURCED WORLDWIDE

LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates

Cardiovascular

Oncology

Ophthalmology

Inflammatory Disease

see other therapeutic areas